Andrew Frederick Wilks

This inventor holds 34 USPTO granted patents and 5 published patent applications, plus 8 CIPO patents and 7 EPO patents, primarily in Kinase Inhibitors. Top assignees: Ym Biosciences Australia Pty Ltd., Ludwig Institute for Cancer Research Limited, Cytopia Research Pty Ltd. Active years: 1997-2017.

USPTO Granted Patents = 34 (Patent Applications = 5)

% Patents Active = 79.4

CIPO Patents = 8 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 3.8

ph-index = 9

Forward Citations = 312(Granted Patents)

Location History:

Doneaster East, AU (1997 - 1999)
Doncaster East, AU (1999 - 2001)
Richmond, AU (2013 - 2016)
South Yarra, AU (2001 - 2017)

Company Filing History:

10 out of 18

Ym Biosciences Australia Pty Ltd.

patents

9 out of 530

Ludwig Institute for Cancer Research Limited

patents

4 out of 4

Cytopia Research Pty Ltd

Helsinki University Licensing, Ltd.

patents

8. 1 out of 1

Vengenics Pty Limited

patent

9. 1 out of 1

Ym Biosicences Australia Pty Ltd

patent

10. 2 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2017

Loading Chart...

Areas of Expertise:

Tubulin Inhibitors

VEGF-D Polypeptides

Kinase Inhibitors

Phenyl Amino Pyrimidines

Pyrazine Compounds

Janus Kinase

Antibody Diagnostics

Wound Healing

Protein Tyrosine Kinase

Growth Factors

Vascular Endothelial Growth Factor

Crystal Structure

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9732046 - Substituted 1,2,4-triazines as tubulin inhibitors (2017-08-15),

2. 9238628 - Phenyl amino pyrimidine compounds and uses thereof (2016-01-19),

3. 9233934 - Phenyl amino pyrimidine compounds and uses thereof (2016-01-12),

4. 9139560 - Substituted pyrazines as tubulin inhibitors (2015-09-22),

5. 8759286 - Pharmaceutical compositions comprising a VEGF-D polypeptide (2014-06-24),

6. 8486941 - Phenyl amino pyrimidine compounds and uses thereof (2013-07-16),

7. 8445234 - Methods of making VEGF-D polypeptides (2013-05-21),

8. 8394806 - 2-phenyl pyrazines as tubulin inhibitors (2013-03-12),

9. 8329737 - Benzimidazoles as selective kinase inhibitors (2012-12-11),

10. 8227410 - Methods of stimulating wound healing by administration of vascular endothelial growth factor D (VEGF-D) (2012-07-24),

11. 8084456 - Pyrazine-based tubulin inhibitors (2011-12-27),

12. 7981900 - 2-phenyl pyrimidines which are tubulin inhibitors (2011-07-19),

13. 7928061 - Methods of using VEGF-D polypeptides (2011-04-19),

14. 7871798 - Mammalian cells that express VEGF-D polypeptides (2011-01-18),

15. 7795206 - Peptide that inhibits janus kinase (2010-09-14),

Title: Andrew Frederick Wilks: A Pioneer in Kinase Inhibitor Innovations

Introduction

Andrew Frederick Wilks is an accomplished inventor residing in South Yarra, Australia. With an impressive portfolio, he holds 34 patents, showcasing his dedication to advancing medical research and treatment through innovative compounds.

Latest Patents

Wilks’ recent patents highlight his focus on developing novel therapeutic agents. One significant patent is for "Substituted 1,2,4-triazines as tubulin inhibitors," which describes compounds formulated to modulate microtubule polymerization and treat associated disease states. Additionally, these compounds demonstrate potential in addressing kinase-associated disease states. Another notable patent is for "Phenyl amino pyrimidine compounds and uses thereof," which centers on compounds that inhibit protein kinases, particularly targeting JAK2 kinases. These innovative kinase inhibitors offer new avenues for treating various diseases, including immunological, inflammatory, viral, metabolic, and hyperproliferative conditions such as cancer.

Career Highlights

Throughout his career, Wilks has made remarkable contributions to pharmaceutical research, primarily through his work with Ym Biosciences Australia Pty Ltd and the Ludwig Institute for Cancer Research Limited. His dedication to innovation has propelled advancements in treatments related to critical health issues.

Collaborations

Andrew Wilks has worked alongside several notable professionals, including Christopher John Burns and Marc Gregory Achen. These collaborations have fostered a rich environment for research and development, enhancing the quality and impact of his inventions.

Conclusion

Andrew Frederick Wilks stands as a significant figure in the field of medical research, with an extensive patent portfolio that reflects his passion and commitment to innovation. His work continues to pave the way for advancements in treatments for various diseases, demonstrating the importance of inventive minds in the improvement of healthcare.